• Is AI The Key To Earlier Detection Of Pharmaceutical Safety Risks?

    Bio-IT WorldPost-marketing surveillance generates an unprecedented volume of safety data. Pharmacovigilance teams must continuously evaluate evidence from Individual Case Safety Reports (ICSRs), clinical studies, scientific literature, electronic health records, patient registries, and real-world data sources. The challenge is no longer data collection, but the timely detection and interpretation of clinically meaningful safety signals amid increasing data complexity.

    Oct 8, 2026

  • MIT Microscope Captures Whole-Brain Voltage Activity at Millisecond Speed, Opening New Doors for Neurotech and Drug Discovery

    Bio-IT World | A new high-speed microscope developed at MIT can image electrical activity across an entire zebrafish brain 200 times per second, a speed that lets researchers follow individual neuronal spikes in near real time. The work, published in Nature Methods and led by Ed Boyden's group at MIT, may give biotech and pharmaceutical researchers a faster, more direct way to see how neural circuits behave and how they might respond to intervention.

    Oct 7, 2026

  • Record-Setting Brain Organoid Holds Vast Medical Potential

    Bio-IT World | Science is at a “magical moment in time” where advances in brain organoid technology and artificial intelligence (AI) are converging to both speed up and derisk the entire drug development process. Human knowledge is poised to take major leaps forward with the discovery of molecular and electrophysiological disease fingerprints in laboratory-grown organoids, models of the human brain. This will change how lab-based drug testing is approached as well as usher in an era of “clinical trials in a vial” to model how the brain, and eventually the entire body, will respond to treatments before people enter studies.

    Oct 6, 2026

  • Follow the Money: Gene Therapy, Pediatric Brain Cancer CAR T, Thyroid Eye Disease

    Bio-IT World | Funding news from around the biotech space including investments in colon cancer immunotherapy, obesity RNAi, in vivo CAR T, autoimmune Tregs, hepatitis D, more.

    Oct 1, 2026